Orthocell spikes on research result

Nerve technology developer Orthocell (ASX:OCC) has reported a study validating ‘high quality nerve repair’ from its CelGro treatment. The pre-clinical study indicated CelGro facilitated the regeneration of severed peripheral nerves, returning them to normal nerve structure. This reinforces earlier human trials that CelGro restored nerve sensation, reducing the need for sutures. Orthocell managing director, Paul…